Inhibition of tumor necrosis factor-α with anti-diabetic agents

Diabetes Research and Clinical Practice

Volumn 43, Issue 3, 1999, Pages 147-154

  Fukuzawa, M ^a   Satoh, J ^a   Qiang, X ^a   Miyaguchi, S ^a   Sakata, Y ^a   Nakazawa, T ^a   Ikehata, F ^a   Ohta, S ^a   Toyota, T ^a  

^a TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Glibenclamide; Gliclazide; Insulin resistance; TNF ; Troglitazone

Indexed keywords

ANTIDIABETIC AGENT; GLIBENCLAMIDE; GLICLAZIDE; TROGLITAZONE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CYTOLYSIS; HUMAN; HUMAN CELL; IMMUNOMODULATION; INSULIN RESISTANCE; INSULIN SENSITIVITY; MALE; MONONUCLEAR CELL; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PROTEIN SYNTHESIS INHIBITION;

ANIMALS; BIOLOGICAL ASSAY; CELLS, CULTURED; CHROMANS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GLICLAZIDE; GLYBURIDE; HUMANS; HYPOGLYCEMIC AGENTS; INTERLEUKIN-1; INTERLEUKIN-6; MALE; MICE; MICE, INBRED BALB C; THIAZOLES; THIAZOLIDINEDIONES; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0032905708     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8227(99)00005-4     Document Type: Article

References (41)

1. Tanaka S.-I., Seino H., Satoh J. et al. Increased in vivo production of tumor necrosis factor after development of diabetes in nontreated, long-term diabetic BB rats. Clin. Immunol. Immunopathol. 62:1992;258-263.
2. Sagara M., Satoh J., Zhu X-P. et al. Inhibition with N-acetylcysteine of enhanced production of tumor necrosis factor in streptozotocin-induced diabetic rats. Clin. Immunol. Immunopathol. 71:1994;333-337.
3. Morohoshi M., Fujisawa K., Uchimura I., Numano F. Glucose-dependent interleukin 6 and tumor necrosis factor production by human peripheral blood monocytes in vitro. Diabetes. 45:1996;954-959.
4. Hotamisligil G.S., Spiegelman B.M. Tumor necrosis factor a: a key component of the obesity-diabetes link. Diabetes. 43:1994;1271-1278.
5. Nishimura S., Satoh J, Toyota T. Serum TNF-α levels and diabetic complications in NIDDM patients. Diabetologia (Suppl.). 40:1997;A601.
6. Feinstein R., Kanety H., Papa M.Z., Lunenfeld B., Karasik A. Tumor necrosis factor-α suppress insulin-induced tyrosine phosphorylation of insulin receptor and its substrates. J. Biol. Chem. 268:1993;26055-26058.
7. Hotamisligil G.S., Shargill N.S., Spiegelman B.M. Adipose expression of tumor necrosis factor-α: direct role in obesity-linked insulin resistance. Science. 259:1993;87-90.
8. Fukuzawa M., Satoh J., Sagara M. et al. Angiotensin converting enzyme inhibitors suppress production of tumor necrosis factor-α in vitro and in vivo. Immunopharmacology. 36:1997;49-55.
9. Sagara M., Satoh J., Wada R. et al. Inhibition of development peripheral neuropathy in streptozotocin-induced diabetic rats with N-acetylcysteine. Diabetologia. 39:1996;263-269.
10. Fukuzawa M., Satoh J., Muto G. et al. Inhibitory effect of nicotinamide on in vitro and in vivo production of tumor necrosis factor-α Immunol. Lett. 59:1997;7-11.
11. Ferner R.E., Chaplin S. The relationship between the pharmacokinetics and pharmacodynamic effects of oral hypoglycaemic drugs. Clin. Pharmcokinet. 12:1987;379-401.
12. Fujiwara T., Yoshioka S., Yoshioka T., Ushiyama I., Horikoshi H. Characterization of new oral antidiabetic agent CS-045. Studies in KK and ob/ob mice and Zucker fatty rats. Diabetes. 37:1988;1549-1558.
13. Satoh J., Seino H., Abo T. et al. Recombinant human tumor necrosis factor a suppresses autoimmune diabetes in nonobese diabetic mice. J. Clin. Invest. 84:1989;1345-1348.
14. Portha B., Serradas P. Improvement in glucose-induced insulin secretion in diabetic rats after long-term gliclazide treatment. A comparative study using different models of non-insulin-dependent diabetes mellitus induced by neonatal streptozotocin. Am. J. Med. 90:1991;15S-21.
15. Qiang X., Satoh J., Sagara M. et al. Gliclazide inhibits diabetic neuropathy irrespective of blood glucose levels in streptozotocine-induced diabetic rats. Metabolism. 47:1998;977-981.
16. Holmes B., Heel R.C., Brogden R.N., Speight T.M., Avery G.S. Gliclazide. A preliminary review of its pharmacodynamic properties and therapeutic efficacy in diabetes mellitus. Drugs. 27:1984;301-327.
17. Ma A., Kamp M., Bird D., Howlett V., Cameron D.P. The effect of long term gliclazide administration on insulin secretion and insulin sensitivity. Aust. New Zealand J. Med. 19:1989;44-49.
18. Scott N.A., Jennings P.E., Brown J., Belch J.J. Gliclazide: a general free radical scavenger. Eur. J. Pharmacol. 208:1991;175-177.
19. Collier A., Watson H.H., Patrick A.W., Ludlam C.A., Clarke B.F. Effect of glycaemic control, mefformin and gliclazide on platelet density and aggregability in recently diagnosed type 2 (non-insulin-dependent) diabetic patients. Diabetes Metab. 15:1989;420-425.
20. 2 formation in normal and streptozotocin-induced diabetic animals. Jpn. J. Pharmacol. 33:1983;965-970.
21. Chaudri G., Clark I.A. Reactive oxygen species facilitate the in vitro and in vivo lipopolysaccharide-induced release of tumor necrosis factor. J. Immunol. 143:1989;1290-1294.
22. Tannenbaum C.S., Hamilton T.A. Lipopolysaccharide-induced gene expression in murine peritoneal macrophages is selectively suppressed by agents that elevate intracellular cAMP. J. Immunol. 142:1989;1247-1280.
23. Eisenhut T., Shinha B., Wolfers E.G., Semmler J., Siess W., Endres S. Prostacyclin analogs suppress the synthesis of tumor necrosis factor-α in LPS-stimulated human peripheral blood mononuclear cells. Immunopharmacology. 26:1993;259-264.
24. Jiang C., Ting A.T., Seed B. PPARγ agonists inhibit production of monocyte inflammatory cytokines. Nature. 391:1998;82-86.
25. Lehmann J.M., Moore L.B., Smith-Oliver T.A., Wilkison W.O., Willson T.M., Kliewer S.A. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ). J. Biol. Chem. 270:1995;12953-12956.
26. Fujiwara T., Yoshioka S., Yoshioka T., Ushiyama I., Horikoshi H. Characterization of new oral antidiabetic agent CS-045. Studies in KK and ob/ob mice and Zucker fatty rats. Diabetes. 37:1988;1549-1558.
27. Horikoshi H., Yoshioka T., Kawasaki T et al. Troglitazone (CS-045), a new antidiabetic drug. Ann. Rep. Sankyo Lab. 46:1994;1-57.
28. Ohsumi J., Sakakibara S., Yamaguchi J. et al. Troglitazone prevents the inhibitory effects of inflammatory cytokines on insulin-induced adipocyte differentiation in 3T3-L1 cell. Endocrinol. 135:1994;2279-2282.
29. Szalkowski D., Carrington S.W., Berger J., Zhang B. Antidiabetic thiazolidinediones block the inhibitory effect of tumor necrosis factor-α on differentiation, insulin-stimulated glucose uptake, and gene expression in 3T3L1 cells. Endocrinology. 136:1995;1474-1481.
30. Schulze-Osthoff K., Bakker A. C., Vonhaesebroeck B., Beyaert R., Jacob W. A., Fiers W. Cytotoxic activities of tumor necrosis factor is mediated by early damage of mitochondrial functions. J. Biol. Chem. 267:1992;5317-5323.
31. O'donnel V.B., Spycher S., Azzi A. Involvement of oxidants and oxidantgenerating enzyme in tumor necrosis factor-α-mediated apoptosis: role for lipoxygenase pathway but not mitochondrial respiratory chain. Biochem. J. 310:1995;133-141.
32. Haliday E.M., Ramesha C.S., Ringold G. TNF induces c-fos via a novel pathway requiring conversion of arachidonic acid to lipoxygenase metabolise. EMBO J. 10:1991;109-115.
33. Nagasaka Y., Kaku K., Nakamura K., Kaneko T. The new oral hypoglycemic agent, troglitazone inhibits the lipid peroxidation of human plasma low density lipoprotein in vitro. Biochem. Pharmacol. 50:1995;1109-1111.
34. Saghizadeh M., Ong J. M., Garvey W.T., Henry R. R., Kern P.A. The expression of TNF alpha by human muscle. Relationship to insulin resistance. J. Clin. Invest. 97:1996;1111-1116.
35. Okuno A., Tamemoto H., Tobe K. et al. Troglitazone increases the number of small adipose tissue mass in obese Zucker rats. J. Clin. Invest. 101:1998;1345-1361.
36. Murase K., Odaka H., Suzuki M., Tayuki N., Ikeda H. Pioglitazone time-dependently reduces tumour necrosis factor-alpha level in muscle and improves metabolic abnormalities in Wistar fatty rats. Diabetologia. 41:1998;257-264.
37. Van der Poll T., Romijn J.A., Endert E., Borm J.J., Buller H.R., Sauerwein H.P. Tumor necrosis factor mimics the metabolic response to acute infection in healthy humans. Am. J. Physiol. 261:1991;E457-E465.
38. McCall J.L., Tuckey J.A., Parry B.R. Serum tumour necrosis factor alpha and insulin resistance in gastrointestinal cancer. Br. J. Surg. 79:1992;1361-1363.
39. Kirchhofer D., Tschopp T. B., Hadvary P., Baumgartner H. R. Endothelial cells stimulated with tumor necrosis factor-alpha express varying amounts of tissue factor resulting in homogenous fibrin deposition in a native blood flow system. Effects of thrombin inhibitors. J. Clin. Invest. 93:1994;2073-2083.
40. Dawson D.A., Martin D., Hallenbeck J.M. Inhibition of tumor necrosis factoralpha reduces focal cerebral ischemic injury in the spontaneously hypertensive rat. Neurosci. Lett. 218:1996;41-44.
41. Qiang X., Satoh J., Sagara M. et al. Inhibitory effect of troglitazone on diabetic neuropathy in streptozotocin-induced diabetic rats. Diabetologia. 41:1998;1321-1326.